Cell and Gene Therapy CRO Market Analysis by Type of Genetic Modification Ex vivo and In vivo Approaches

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy CRO Market- (By Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), By Type of Genetic Modification (Ex vivo and In vivo), By Stage of Development (Discovery, Preclinical, and Clinical)), By Therapeutic Area, By End-user, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Cell and Gene Therapy CRO Market is valued at US$ 1.46 Bn in 2023, and it is expected to reach US$ 2.43 Bn by 2031, with a CAGR of 6.7% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2521

Gene therapies are transforming contemporary medicine by targeting the underlying causes of diseases rather than merely alleviating symptoms. These therapies have shown significant promise in treating conditions traditionally resistant to conventional interventions, including ocular disorders, neurological diseases, and various forms of cancer.

A prominent strategy in this field involves the use of viral vectors to deliver therapeutic genes directly to cardiac or arterial cells. Clinical evidence has demonstrated favorable outcomes in managing cardiovascular conditions, such as heart failure and inherited cardiac disorders, underscoring the potential for broader clinical adoption.

Market growth is further supported by substantial investments in gene therapy research and development from both public and private sectors. Consequently, the cell and gene therapy segment addressing coronary artery disease is expected to witness strong expansion in the coming years. However, maintaining a skilled workforce within the global cell and gene therapy contract research organization (CRO) sector remains a critical challenge, potentially constraining the availability of qualified professionals essential for sustaining research, development, and clinical operations.

List of Prominent Players in the Cell and Gene Therapy CRO Market:
• Altasciences
• Allucent
• CMIC
• Labcorp
• Linical
• Medpace
• PPD
• Precision for Medicine
• QPS
• Syneos Health
• CMED
• ICON
• Pharmalex
• Novotech

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The cell and gene therapy market for cardiovascular and related chronic diseases is experiencing strong growth, fueled by the rising prevalence of conditions such as cardiovascular disorders, cancer, and rare genetic diseases. Growing recognition of gene therapy as an effective treatment modality, coupled with substantial government funding and supportive policy initiatives, is accelerating adoption and market expansion.

Challenges:
Despite promising prospects, the growth of the cell and gene therapy contract research organization (CRO) sector faces notable challenges. High capital investment requirements, a limited pool of skilled professionals, and fragmented regulatory frameworks-exacerbated by disruptions during the COVID-19 pandemic-have impeded progress, particularly in emerging markets.

The manufacturing and delivery of gene therapies remain resource-intensive, restricting patient access, especially for individuals without comprehensive insurance coverage. The lack of standardized reimbursement models and limited insurance support further constrains affordability. Additionally, uncertainties regarding the long-term safety and efficacy of gene therapies contribute to cautious uptake among healthcare providers and payers, particularly in the treatment of rare diseases. The COVID-19 pandemic further disrupted clinical trials through site closures, supply chain interruptions, and operational constraints, delaying overall market development.

Regional Trends:
North America is expected to retain a dominant position in the cell and gene therapy CRO market, driven by high cardiovascular disease prevalence, substantial research and development investment, technological advancements, favorable government initiatives, and increasing healthcare expenditures. Europe also represents a significant market segment, supported by a large patient population, rising incidence of chronic diseases, heightened awareness of gene therapy solutions, and expanding research funding. Collectively, these factors underpin sustained growth in the gene therapy market across both regions.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2521

Recent Developments:
• In January 2024, ICON plc announced that Chief Financial Officer Brendan Brennan would resign in the final period of this year to pursue an adventure within the CRO field. To facilitate a seamless transfer to the new Chief Financial Officer, Brendan will continue in his current position and join the firm. A hunt for ICON's next chief financial officer has begun.
• In March 2024, Novotech announced that the Commission for Drugs for Humans of the European Medicines Agency (EMA) has recommended that Fabhalta (iptacopan) be approved for marketing to treat adulthood with nocturnal paroxysms of hemoglobin (PNH) and hemolytic anemia.

Segmentation of Cell and Gene Therapy CRO Market
By Type of Cell Therapy
• CAR-NK
• CAR-T
• TCR-T
• Others
By Type of Genetic Modification
• Ex vivo
• In vivo
By Stage of Development
• Discovery
• Preclinical
• Clinical
By Therapeutic Area
• Blood Disorders
• Cardiovascular Disorders
• Dermatological Disorders
• Immunological Disorders
• Infectious Diseases
• Metabolic Disorders
• Musculoskeletal Disorders
• Neurological Disorders
• Oncological Disorders
• Rare Diseases
• Other disorders
Cell and Gene Therapy CRO Market-By End-Users
• Industry Players
• Non-Industry Players
Cell and Gene Therapy CRO Market-By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/cell-and-gene-therapy-cro-market/2521

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.